DrugPatentWatch Database Preview
REXULTI Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Rexulti, and when can generic versions of Rexulti launch?
Rexulti is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-nine patent family members in twenty-five countries.
The generic ingredient in REXULTI is brexpiprazole. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the brexpiprazole profile page.
Summary for REXULTI
| International Patents: | 29 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 44 |
| Clinical Trials: | 1 |
| Patent Applications: | 47 |
| Drug Prices: | Drug price information for REXULTI |
| DailyMed Link: | REXULTI at DailyMed |
Generic Entry Opportunity Date for REXULTI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for REXULTI
| Drug Class | Atypical Antipsychotic |
Synonyms for REXULTI
| 2(1H)-Quinolinone, 7-(4-(4-benzo(b)thien-4-yl-1-piperazinyl)butoxy)- |
| 2J3YBM1K8C |
| 7-(4-(4-(1-Benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one |
| 7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one |
| 7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1H)-Quinolinone |
| 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one |
| 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one |
| 7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one |
| 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one |
| 913611-97-9 |
| AK171366 |
| AKOS025291100 |
| AX8306230 |
| BC600277 |
| BREXPIPRAZOLE |
| Brexpiprazole (JAN/USAN/INN) |
| Brexpiprazole [USAN:INN] |
| Brexpiprazole(OPC34712) |
| CHEBI:134716 |
| CHEMBL2105760 |
| CS-2108 |
| D0P0OU |
| D10309 |
| DB09128 |
| DTXSID40238527 |
| FT-0712292 |
| GTPL7672 |
| HY-15780 |
| KS-0000063N |
| MFCD27987920 |
| MolPort-039-063-477 |
| MolPort-046-033-502 |
| OPC 34712 |
| OPC-34712 |
| OPC34712 |
| Rexulti (TN) |
| s4639 |
| SCHEMBL1037592 |
| SCHEMBL14772509 |
| UNII-2J3YBM1K8C |
| ZINC84758479 |
| ZKIAIYBUSXZPLP-UHFFFAOYSA-N |
US Patents and Regulatory Information for REXULTI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-006 | Jul 10, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-004 | Jul 10, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-005 | Jul 10, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-005 | Jul 10, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-001 | Jul 10, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Otsuka Pharm Co Ltd | REXULTI | brexpiprazole | TABLET;ORAL | 205422-004 | Jul 10, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Non-Orange Book US Patents for REXULTI
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,206,167 | Piperazine-substituted benzothiophenes for treatment of mental disorders | ➤ Sign Up |
| 9,480,686 | Piperazine-substituted benzothiophenes for treatment of mental disorders | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for REXULTI
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Mexico | 2007012626 | ➤ Sign Up |
| Austria | 496911 | ➤ Sign Up |
| Cyprus | 1111206 | ➤ Sign Up |
| Japan | 4315393 | ➤ Sign Up |
| Taiwan | 200716619 | ➤ Sign Up |
| India | 855DEN2012 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
